{"id":33994,"date":"2025-05-23T19:00:29","date_gmt":"2025-05-23T11:00:29","guid":{"rendered":"https:\/\/flcube.com\/?p=33994"},"modified":"2025-05-23T19:00:30","modified_gmt":"2025-05-23T11:00:30","slug":"roches-susvimo-gets-fda-approval-for-diabetic-retinopathy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33994","title":{"rendered":"Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy"},"content":{"rendered":"\n

Swiss giant Roche (SWX: ROG<\/a>, OTCMKTS: RHHBY<\/a>) announced that its Susvimo (ranibizumab) 100mg\/mL intravitreal ocular implant has received another indication approval from the US Food and Drug Administration (FDA). The approval extends Susvimo’s use to treat patients with diabetic retinopathy (DR) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. This marks a further expansion of Susvimo’s therapeutic applications following previous approvals for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).<\/p>\n\n\n\n

Susvimo Mechanism and Delivery<\/strong>
Susvimo is a refillable eye implant surgically inserted into the eye. It provides continuous delivery of a customized formulation of ranibizumab via the Port Delivery Platform, requiring just one refill every nine months. This innovative delivery method ensures sustained treatment with minimal patient burden.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The FDA approval is based on results from the Phase III Pavilion study. The study demonstrated that patients with DR who received Susvimo refills every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale (DRSS). Additionally, none of the participants receiving Susvimo required supplemental treatment at one year. Safety results were consistent with the known profile of Susvimo.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg\/mL intravitreal ocular…<\/p>\n","protected":false},"author":1,"featured_media":33995,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,940,15,939],"class_list":["post-33994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-otcmkts-rhhby","tag-product-approvals","tag-swx-rop"],"yoast_head":"\nRoche's Susvimo Gets FDA Approval for Diabetic Retinopathy - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg\/mL intravitreal ocular implant has received another indication approval from the US Food and Drug Administration (FDA). The approval extends Susvimo's use to treat patients with diabetic retinopathy (DR) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. This marks a further expansion of Susvimo's therapeutic applications following previous approvals for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33994\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche's Susvimo Gets FDA Approval for Diabetic Retinopathy\" \/>\n<meta property=\"og:description\" content=\"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg\/mL intravitreal ocular implant has received another indication approval from the US Food and Drug Administration (FDA). The approval extends Susvimo's use to treat patients with diabetic retinopathy (DR) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. This marks a further expansion of Susvimo's therapeutic applications following previous approvals for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33994\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-23T11:00:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-23T11:00:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33994#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33994\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy\",\"datePublished\":\"2025-05-23T11:00:29+00:00\",\"dateModified\":\"2025-05-23T11:00:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33994\"},\"wordCount\":206,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33994#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2303.webp\",\"keywords\":[\"Diabetes\",\"OTCMKTS: RHHBY\",\"Product approvals\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33994#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33994\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33994\",\"name\":\"Roche's Susvimo Gets FDA Approval for Diabetic Retinopathy - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33994#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33994#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2303.webp\",\"datePublished\":\"2025-05-23T11:00:29+00:00\",\"dateModified\":\"2025-05-23T11:00:30+00:00\",\"description\":\"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg\\\/mL intravitreal ocular implant has received another indication approval from the US Food and Drug Administration (FDA). The approval extends Susvimo's use to treat patients with diabetic retinopathy (DR) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. This marks a further expansion of Susvimo's therapeutic applications following previous approvals for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33994#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33994\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33994#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2303.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2303.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche's Susvimo Gets FDA Approval for Diabetic Retinopathy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33994#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche's Susvimo Gets FDA Approval for Diabetic Retinopathy - Insight, China's Pharmaceutical Industry","description":"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg\/mL intravitreal ocular implant has received another indication approval from the US Food and Drug Administration (FDA). The approval extends Susvimo's use to treat patients with diabetic retinopathy (DR) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. This marks a further expansion of Susvimo's therapeutic applications following previous approvals for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33994","og_locale":"en_US","og_type":"article","og_title":"Roche's Susvimo Gets FDA Approval for Diabetic Retinopathy","og_description":"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg\/mL intravitreal ocular implant has received another indication approval from the US Food and Drug Administration (FDA). The approval extends Susvimo's use to treat patients with diabetic retinopathy (DR) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. This marks a further expansion of Susvimo's therapeutic applications following previous approvals for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).","og_url":"https:\/\/flcube.com\/?p=33994","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-23T11:00:29+00:00","article_modified_time":"2025-05-23T11:00:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33994#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33994"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy","datePublished":"2025-05-23T11:00:29+00:00","dateModified":"2025-05-23T11:00:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33994"},"wordCount":206,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33994#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303.webp","keywords":["Diabetes","OTCMKTS: RHHBY","Product approvals","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33994#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33994","url":"https:\/\/flcube.com\/?p=33994","name":"Roche's Susvimo Gets FDA Approval for Diabetic Retinopathy - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33994#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33994#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303.webp","datePublished":"2025-05-23T11:00:29+00:00","dateModified":"2025-05-23T11:00:30+00:00","description":"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg\/mL intravitreal ocular implant has received another indication approval from the US Food and Drug Administration (FDA). The approval extends Susvimo's use to treat patients with diabetic retinopathy (DR) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. This marks a further expansion of Susvimo's therapeutic applications following previous approvals for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33994#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33994"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33994#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303.webp","width":1080,"height":608,"caption":"Roche's Susvimo Gets FDA Approval for Diabetic Retinopathy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33994#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2303.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33994"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33994\/revisions"}],"predecessor-version":[{"id":33996,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33994\/revisions\/33996"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33995"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}